Amgen and Kyowa Kirin have reported preliminary outcomes from a trial for an atopic dermatitis treatment. The trial, which appears to be part of a phase 3 study, has yielded results on the long-term safety of the treatment, specifically a medication called rocatinlimab. The specific details and outcomes of the trial are not entirely clear, with some reports referencing an "ascend" trial and others an "ignite" study.